Based on the data collected for this study, we identified that compared to other types of drugs in our dataset, IL-17 inhibitors achieve better efficacy in patients with more severe psoriasis (Fig. 5b, c), while MTX drugs have a lower ability in preventing the progression from non-PsA to PsA (Fig. 5d), providing with clinicians with useful insights in drug selection and prescription. Here, IL17A is linked to psoriasis.